• Progressed US market entry, refining digital marketing strategy
• Added new Australian pharmacy wholesaler and pharmacies
• Launched three new products in Q1 FY26

EZZ Life Science Holdings Ltd (ASX: EZZ) presented its Quarterly Activities Report and Appendix 4C for the period ended 30 September 2025 (Q1 FY26). Key highlights include: Progressed US market entry, refining digital marketing strategy to focus on performance-based campaigns and retail channel expansion; Added one new Australian pharmacy wholesaler and three new pharmacies to the national distribution network; Launched three new products in Q1 FY26: EZZ Breast Health Capsule, EZZ Women's Bone Strength Capsule, and EZZ R-21 Ergothioneine Capsule. Receipts from customers totalled $11.5m, down 25.4% on the prior corresponding period due to deferred receipts from a livestreaming campaign and seasonally lower Chinese retail activity. Operating expenditure increased due to additional inventory purchases, US market entry marketing, and M&A evaluation costs. The company closed the quarter with a strong cash balance of $17.3m and remains debt-free. Looking ahead, key priorities include scaling the EZZDAY brand in the US, driving performance in Southeast Asia, accelerating growth in Australian retail, and continuing product innovation.

The company expects higher sales in Q2 ahead of the 11.11 Shopping Festival.

EZZ remains focused on executing its global growth strategy through innovation, market expansion and strong local partnerships. Key priorities include scaling the EZZDAY brand in the US, driving performance in Southeast Asia, accelerating growth in Australian retail, and continuing product innovation.